TERN250117P16000
- 0.00
- 0.000.00%
Terns Pharmaceuticals Newsroom
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals Positioned for Success With Promising Oral Therapy TERN-601 Amid Novo Nordisk's Setback
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $14
Mizuho Securities Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
Merck-Hansoh Deal for Oral GLP-1 Hurts Obesity Drug Developers
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Amy Burroughs Bought 423% More Shares In Terns Pharmaceuticals
Terns Pharmaceuticals CEO & Director Acquires 423% More Stock
Insider Purchase: Chief Executive Officer of $TERN (TERN) Buys 15,450 Shares
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)
Oppenheimer Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Terns Pharmaceuticals(TERN.US) With Hold Rating, Maintains Target Price $7.5
Hold Rating on Terns Pharmaceuticals' TERN-701 Due to Uncertain Efficacy Despite Promising Safety Profile
Terns's Stock Soars as Analysts Cheer Leukemia Data - and Predict More Gains
Express News | HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $7.5 Price Target
Express News | Terns Pharmaceuticals Inc : Jefferies Raises Target Price to $34 From $30
Terns Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Terns Pharmaceuticals Price Target Raised to $20.00/Share From $17.00 by Oppenheimer
Terns Pharma Analyst Ratings